NCT03890731: A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

NCT03890731
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be currently participating in any Bayer-sponsored regorafenib study
Exclusions: 
https://ClinicalTrials.gov/show/NCT03890731

Comments are closed.

Up ↑